| First Author | Ahluwalia MS | Year | 2010 |
| Journal | Cancer Lett | Volume | 298 |
| Issue | 2 | Pages | 139-49 |
| PubMed ID | 20947248 | Mgi Jnum | J:165555 |
| Mgi Id | MGI:4837756 | Doi | 10.1016/j.canlet.2010.08.014 |
| Citation | Ahluwalia MS, et al. (2010) Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett 298(2):139-49 |
| abstractText | Glioblastoma (GBM) is an extremely aggressive, infiltrative tumor with a poor prognosis. The regulatory approval of bevacizumab for recurrent GBM has confirmed that molecularly targeted agents have potential for GBM treatment. Preclinical data showing that SRC and SRC-family kinases (SFKs) mediate intracellular signaling pathways controlling key biologic/oncogenic processes provide a strong rationale for investigating SRC/SFK inhibitors, e.g., dasatinib, in GBM and clinical studies are underway. The activity of these agents against solid tumors suggests that they may also be useful in treating brain metastases. This article reviews the potential for using SRC/SFK inhibitors to treat GBM and brain metastases. |
